Gown Allen M, Fulton Regan S, Kandalaft Patricia L
PhenoPath Laboratories, Seattle, WA, USA.
Pacific Pathology Partners, Seattle, WA, USA.
Histopathology. 2016 Jan;68(1):86-95. doi: 10.1111/his.12877.
This review summarizes the three major breast-associated markers that can be of assistance in evaluating metastatic carcinomas for which a breast primary diagnosis is entertained. These markers include gross cystic disease fluid protein-15 (GCDFP-15), mammaglobin, and GATA3. The first two are cytoplasmic markers that show comparable sensitivities for breast cancer, although relatively few of the published studies have employed the same antibodies against the target molecule, making direct comparisons challenging. GATA3 is a nuclear transcription factor that shows superior sensitivity to GCDFP-15 and mammaglobin. However, the specificity of GATA3 can pose challenges, inasmuch as carcinomas of the bladder and other sites can show significant levels of positivity. Determination of the optimal panel of antibodies employed in a given clinical setting will thus depend on the non-breast tumours included in the differential diagnosis.
本综述总结了三种主要的乳腺相关标志物,它们有助于评估疑似原发性乳腺癌的转移性癌。这些标志物包括乳腺囊肿病液蛋白-15(GCDFP-15)、乳腺珠蛋白和GATA3。前两种是细胞质标志物,对乳腺癌显示出相当的敏感性,尽管相对较少的已发表研究使用针对靶分子的相同抗体,这使得直接比较具有挑战性。GATA3是一种核转录因子,对GCDFP-15和乳腺珠蛋白显示出更高的敏感性。然而,GATA3的特异性可能带来挑战,因为膀胱和其他部位的癌也可显示出显著的阳性水平。因此,在特定临床环境中确定最佳抗体组合将取决于鉴别诊断中所包含的非乳腺肿瘤。